New developments in CAR-T cell therapies including controversial ones
In the second part of our cell therapy series this week, we take on three quite different issues.
These include the following:
- A new dual CAR in development
- Where cell therapy may be heading and how to address the limitations
- The Cellectis CS–1/SLAMF7 clinical hold
Not all CAR T cell therapies are going to end up as a bridge to transplant – some of them are clearly intended to be more efficacious than their predecessors – but along the way the trials, tribulations and clinical challenges continue apace.
These are all meaty topics to consider, so with out much further ado, let’s roll…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from recent events, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
